These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35507661)

  • 1. Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain.
    Gray MD; Feng J; Weidle CE; Cohen KW; Ballweber-Fleming L; MacCamy AJ; Huynh CN; Trichka JJ; Montefiori D; Ferrari G; Pancera M; McElrath MJ; Stamatatos L
    Sci Adv; 2022 May; 8(18):eabm3948. PubMed ID: 35507661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization.
    Parks KR; MacCamy AJ; Trichka J; Gray M; Weidle C; Borst AJ; Khechaduri A; Takushi B; Agrawal P; Guenaga J; Wyatt RT; Coler R; Seaman M; LaBranche C; Montefiori DC; Veesler D; Pancera M; McGuire A; Stamatatos L
    Cell Rep; 2019 Dec; 29(10):3060-3072.e7. PubMed ID: 31801073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.
    Jardine JG; Ota T; Sok D; Pauthner M; Kulp DW; Kalyuzhniy O; Skog PD; Thinnes TC; Bhullar D; Briney B; Menis S; Jones M; Kubitz M; Spencer S; Adachi Y; Burton DR; Schief WR; Nemazee D
    Science; 2015 Jul; 349(6244):156-61. PubMed ID: 26089355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody.
    Scharf L; West AP; Gao H; Lee T; Scheid JF; Nussenzweig MC; Bjorkman PJ; Diskin R
    Proc Natl Acad Sci U S A; 2013 Apr; 110(15):6049-54. PubMed ID: 23524883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short CDRL1 in intermediate VRC01-like mAbs is not sufficient to overcome key glycan barriers on HIV-1 Env.
    Agrawal P; Knudsen ML; MacCamy A; Hurlburt NK; Khechaduri A; Salladay KR; Kher GM; Kallur Siddaramaiah L; Stuart AB; Bontjer I; Shen X; Montefiori D; Gristick HB; Bjorkman PJ; Sanders RW; Pancera M; Stamatatos L
    J Virol; 2024 Oct; 98(10):e0074424. PubMed ID: 39240111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for germline antibody recognition of HIV-1 immunogens.
    Scharf L; West AP; Sievers SA; Chen C; Jiang S; Gao H; Gray MD; McGuire AT; Scheid JF; Nussenzweig MC; Stamatatos L; Bjorkman PJ
    Elife; 2016 Mar; 5():. PubMed ID: 26997349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors.
    Yacoob C; Pancera M; Vigdorovich V; Oliver BG; Glenn JA; Feng J; Sather DN; McGuire AT; Stamatatos L
    Cell Rep; 2016 Nov; 17(6):1560-1570. PubMed ID: 27806295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies.
    Duan H; Chen X; Boyington JC; Cheng C; Zhang Y; Jafari AJ; Stephens T; Tsybovsky Y; Kalyuzhniy O; Zhao P; Menis S; Nason MC; Normandin E; Mukhamedova M; DeKosky BJ; Wells L; Schief WR; Tian M; Alt FW; Kwong PD; Mascola JR
    Immunity; 2018 Aug; 49(2):301-311.e5. PubMed ID: 30076101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier.
    Bonsignori M; Scott E; Wiehe K; Easterhoff D; Alam SM; Hwang KK; Cooper M; Xia SM; Zhang R; Montefiori DC; Henderson R; Nie X; Kelsoe G; Moody MA; Chen X; Joyce MG; Kwong PD; Connors M; Mascola JR; McGuire AT; Stamatatos L; Medina-Ramírez M; Sanders RW; Saunders KO; Kepler TB; Haynes BF
    Immunity; 2018 Dec; 49(6):1162-1174.e8. PubMed ID: 30552024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
    LaBranche CC; McGuire AT; Gray MD; Behrens S; Kwong PDK; Chen X; Zhou T; Sattentau QJ; Peacock J; Eaton A; Greene K; Gao H; Tang H; Perez LG; Chen X; Saunders KO; Kwong PD; Mascola JR; Haynes BF; Stamatatos L; Montefiori DC
    PLoS Pathog; 2018 Nov; 14(11):e1007431. PubMed ID: 30395637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors.
    Lin YR; Parks KR; Weidle C; Naidu AS; Khechaduri A; Riker AO; Takushi B; Chun JH; Borst AJ; Veesler D; Stuart A; Agrawal P; Gray M; Pancera M; Huang PS; Stamatatos L
    Immunity; 2020 Oct; 53(4):840-851.e6. PubMed ID: 33053332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
    Beltran-Pavez C; Bontjer I; Gonzalez N; Pernas M; Merino-Mansilla A; Olvera A; Miro JM; Brander C; Alcami J; Sanders RW; Sanchez-Merino V; Yuste E
    J Virol; 2022 Jan; 96(1):e0134321. PubMed ID: 34668778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
    McGuire AT; Glenn JA; Lippy A; Stamatatos L
    J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor.
    Kong L; Ju B; Chen Y; He L; Ren L; Liu J; Hong K; Su B; Wang Z; Ozorowski G; Ji X; Hua Y; Chen Y; Deller MC; Hao Y; Feng Y; Garces F; Wilson R; Dai K; O'Dell S; McKee K; Mascola JR; Ward AB; Wyatt RT; Li Y; Wilson IA; Zhu J; Shao Y
    Immunity; 2016 Apr; 44(4):939-50. PubMed ID: 27067056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humanized V(D)J-rearranging and TdT-expressing mouse vaccine models with physiological HIV-1 broadly neutralizing antibody precursors.
    Luo S; Jing C; Ye AY; Kratochvil S; Cottrell CA; Koo JH; Chapdelaine Williams A; Francisco LV; Batra H; Lamperti E; Kalyuzhniy O; Zhang Y; Barbieri A; Manis JP; Haynes BF; Schief WR; Batista FD; Tian M; Alt FW
    Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2217883120. PubMed ID: 36574685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site.
    Gristick HB; von Boehmer L; West AP; Schamber M; Gazumyan A; Golijanin J; Seaman MS; Fätkenheuer G; Klein F; Nussenzweig MC; Bjorkman PJ
    Nat Struct Mol Biol; 2016 Oct; 23(10):906-915. PubMed ID: 27617431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly mutated antibodies capable of neutralizing N276 glycan-deficient HIV after a single immunization with an Env trimer.
    Lee JH; Nakao C; Appel M; Le A; Landais E; Kalyuzhniy O; Hu X; Liguori A; Mullen TM; Groschel B; Abbott RK; Sok D; Schief WR; Crotty S
    Cell Rep; 2022 Mar; 38(10):110485. PubMed ID: 35263576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.
    Lynch RM; Wong P; Tran L; O'Dell S; Nason MC; Li Y; Wu X; Mascola JR
    J Virol; 2015 Apr; 89(8):4201-13. PubMed ID: 25631091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice.
    McGuire AT; Gray MD; Dosenovic P; Gitlin AD; Freund NT; Petersen J; Correnti C; Johnsen W; Kegel R; Stuart AB; Glenn J; Seaman MS; Schief WR; Strong RK; Nussenzweig MC; Stamatatos L
    Nat Commun; 2016 Feb; 7():10618. PubMed ID: 26907590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth.
    Chen X; Zhou T; Schmidt SD; Duan H; Cheng C; Chuang GY; Gu Y; Louder MK; Lin BC; Shen CH; Sheng Z; Zheng MX; Doria-Rose NA; Joyce MG; Shapiro L; Tian M; Alt FW; Kwong PD; Mascola JR
    Immunity; 2021 Feb; 54(2):324-339.e8. PubMed ID: 33453152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.